-  This bill is not active in this session.
 

J01824 Summary:

BILL NOJ01824
 
SAME ASNo Same As
 
SPONSORAKSHAR
 
COSPNSR
 
MLTSPNSR
 
 
Go to top    

J01824 Actions:

BILL NOJ01824
 
06/05/2019REFERRED TO FINANCE
06/12/2019REPORTED TO CALENDAR FOR CONSIDERATION
06/12/2019ADOPTED
Go to top

J01824 Committee Votes:

Go to top

J01824 Floor Votes:

There are no votes for this bill in this legislative session.
Go to top

J01824 Text:

 
Senate Resolution No. 1824
 
BY: Senator AKSHAR
 
        MEMORIALIZING Governor Andrew M. Cuomo to proclaim
        September  2019,  as Pulmonary Fibrosis Month in the
        State of New York
 
  WHEREAS, It is the custom of  this  Legislative  Body  to  recognize
official  months  that  are  set  aside to increase awareness of serious
illnesses that affect the lives of citizens of New York State; and
 
  WHEREAS, Attendant to such concern, and  in  full  accord  with  its
long-standing  traditions,  this  Legislative  Body  is  justly proud to
memorialize Governor Andrew M. Cuomo  to  proclaim  September  2019,  as
Pulmonary Fibrosis Month in the State of New York; and
 
  WHEREAS,  Pulmonary  Fibrosis is a disease of the lungs which occurs
when lung tissue becomes damaged and scarred; when the tissue around the
air sacs in the lungs thickens, it is more difficult for oxygen to  pass
into  the  bloodstream  causing  those with pulmonary fibrosis to become
progressively more short of breath; and
 
  WHEREAS, Scarring associated with pulmonary fibrosis can  be  caused
by many factors making it difficult for doctors to pinpoint the specific
cause of the problem, and in most cases the cause is never found; when a
definite  cause  cannot  be  found,  the  condition is termed Idiopathic
Pulmonary Fibrosis (IPF); and
 
  WHEREAS, The symptoms of pulmonary  fibrosis  vary  from  person  to
person  and  include  shortness  of breath, a dry cough, fatigue, weight
loss, and aching muscles and joints; and
 
  WHEREAS, A lack of clinical understanding  of  IPF  often  leads  to
misdiagnosis,  and  it is estimated more than 50 percent of IPF patients
may be initially misdiagnosed delaying  treatment  and  the  ability  to
perform adequate clinical trials; and
 
  WHEREAS,  It  is  estimated approximately 130,000 Americans have IPF
although there are published estimates suggesting the number may  be  as
high as 200,000; and
 
  WHEREAS,  IPF  is  found  in  equal  proportions  in urban and rural
environments but affects more men than women, the majority of  whom  are
50 years-old or older; and
 
  WHEREAS,  The  average life expectancy from the diagnosis of the IPF
is just 2.8 years, and as many as 80 percent of IPF patients die  within
five years of diagnosis; and
 
  WHEREAS,  Pulmonary  fibrosis  takes  the  lives  of  40,000 or more
individuals in the United States each year, approximately one individual
every 13 minutes; and
 
  WHEREAS, Researchers have several theories  on  the  causes  of  IPF
including:  viruses;  exposure  to tobacco smoke; airborne toxins in the
workplace such as silica dust, asbestos fibers,  grain  dust,  bird  and
 
animal  droppings; certain lung diseases; and even some types of medical
treatments; since IPF often runs in families, heredity is also  believed
to play a role; and
 
  WHEREAS,  The lung scarring that occurs in pulmonary fibrosis cannot
be reversed and no current treatment has proved  effective  in  stopping
the  progression  of  the  disease  although some treatments may improve
symptoms temporarily or slow the disease's progress; and
 
  WHEREAS, Lung transplantation may be the option of last  resort  for
patients with severe IPF; and
 
  WHEREAS,  As  of  July  2018,  there are no confirmed biomarkers for
screening and testing for pulmonary fibrosis; and
 
  WHEREAS, It is imperative there be greater public awareness of  this
serious  health  condition,  and more must be done to encourage research
and activity at the State, local and  national  levels  to  support  the
patients as well as their families; now, therefore, be it
 
  RESOLVED,  This  this Legislative Body pause in its deliberations to
memorialize Governor Andrew M. Cuomo  to  proclaim  September  2019,  as
Pulmonary Fibrosis Month in the State of New York; and be it further
 
  RESOLVED,  That  this  Legislative Body pause further to continue to
support more robust and accelerated research to develop  more  effective
treatments  for pulmonary fibrosis and to ultimately find a cure for the
disease; recognize the courage and  contributions  of  individuals  with
pulmonary  fibrosis  who participate in vital clinical trials to advance
the  knowledge  of  the  disease;  and   commend   the   dedication   of
organizations,  volunteers  and  researchers  from the State of New York
working to improve the quality of life for  individuals  with  pulmonary
fibrosis and the families of those individuals; and be it further
 
  RESOLVED,  That  a  copy  of this Resolution, suitably engrossed, be
transmitted to The Honorable Andrew M. Cuomo, Governor of the  State  of
New York.
Go to top